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Objectives: We aim to identify microRNAs and mRNAs
differentially expressed in papillary thyroid cancer that
correlate with clinical characteristics of the disease.
Methods: Level 3 miR-Seq data and mRNA-Seq data of
thyroid cancer from The Cancer Genome Atlas (TCGA)
were used for analysis. The expression level of microRNAs
and mRNAs between normal and primary tumor samples
were compared. The correlation between differentially
expressed miRNAs/mRNAs and patients’ clinical
characteristics, including tumor size (T1/2 vs. T3/4),
lymph node status, metastatic status, extrathyroidal
extension (ETE), BRAF mutation, and AJCC tumor stage
(TI/II vs. TIII/IV) were tested.
Results: 65 miRs and 2483 mRNAs were differentially
expressed in papillary thyroid carcinoma primary tumors
compared to adjacent normal tissues with more than 2-
fold change. Many differentially expressed miRs were
significantly correlated with BRAFV600E mutation, lymph
node involvement, ETE, tumor stage, tumor size, but not
with tumor metastatic status. The miR-551b was the
second upregulated miRs in primary tumor compared to
normal tissues (7.6 fold, p<0.0001), and was further
increased in tumors from patients with lymph node
metastasis or BRAF mutation. Among differentially
expressed mRNAs, SEMA3D expression was significantly
decreased (31.7 fold, p<0.0001) in PTC, and was further
decreased in tumors from patients with lymph node
metastasis, tumor stage III / IV, ETE, or BRAF mutation.
SEMA3D shows significant negative correlation with miR-
551b in PTC patients (r=-0.66 and p<.0001), and miRDB
predicts SEMA3D as a target of miR-551b. Both miR-551b
and SEMA3D has been reported as a potential
therapeutic target in other cancers [1,2]. Recently,
SEMA3D was included in a 15-gene biomarker panel to
identify malignancy among cytologically indeterminate
thyroid tumors [3]. Therefore, miR-551b and SEMA3D
may play a critical role in thyroid cancer tumorigenesis
and/or progression.
Conclusions: Deregulated miR-551b and SEMA3D may
play a critical role in tumorigenesis and/or progression
and they may serve as potential therapeutic targets in
PTC.
































































































A. Top differentially expressed miRs with >3 fold change. B. Top differentially expressed mRNAs with >20 fold change in PTC.
Thyroid cancer TCGA mRNA-Seq and miRNA-Seq data were compared between the paired normal and primary PTC samples.
miRs and mRNAs that meet the significance cutoff (p-value<0.0001)and with more than 2 fold change were selected for further
association tests with patient clinical characteristics (65miRs and 2483 mRNAs were selected).
















































• The expression of the upregulated miRs, including miR-551b, -31, -221, -222,
-375, -146b, -21, -508, are further increased; and the downregulated miRs,
including miR-139, -20b, -138-1, -7-3, -1179, -7-2, -577, -345, -152, -204, are
further decreased in tumors with BRAFV600E mutation (P<.0001 for BRAF
association test).
• miR-1247, miR-127, miR-134, miR-379 are significantly downregulated in
primary tumors, but their expression was significantly increased in tumors
with BRAFV600E mutation (P<.0001 for BRAF association test).
• Most of the miRs significantly associated with BRAFV600E mutation are also
associated with lymph node involvement, tumor stage III/IV, tumor size 3/4,
or ETE
• None of the differentially expressed miRs are associated with metastatic
status.



























P<.0001 miR-551b is further increased in tumors from
patients with BRAFV600E mutation or lymph node
involvement.
SEMA3D associated with miR-
551b, BRAFV600E mutation, tumor 
stage (III/IV) , ETE, and lymph 
node involvement
• SEM3D is negatively correlated with miR-
551b and is a predicted target of miR-
551b.
• SEMA3D was significantly downregulated in
PTC, and was further decreased in tumors
from patients with lymph node
involvement, BRAFV600E mutation, tumor
stage III/IV, or ETE.
• miR-551b is associated with BRAFV600E
mutation and lymph node involvement.
• SEMA3D, a predicted target of miR-551b, is
associated with BRAFV600E mutation, ETE,
lymph node involvement, and tumor stage
(III/IV).
• Therefore, miR-551b and SEMA3D axis may
play a critical role in thyroid cancer
tumorigenesis and/or progression.
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